Dolon Ltd
Anna Albiero is an experienced consultant and senior analyst at Dolon Ltd since January 2021, specializing in market access strategies for orphan drugs and innovative medicines. Anna has a strong research background, having worked at the University of Cambridge from October 2015 to December 2020, focusing on European policies for stem cell and regenerative medicine as well as molecular cancer diagnostics. Anna earned a PhD in Biological and Biomedical Sciences from the University of Cambridge and holds a Master's in Biomedical Sciences from Leiden University and a Bachelor's in Molecular Biotechnology from Università di Trento. Additionally, Anna has participated in entrepreneurial programs at Cambridge Judge Business School and Cambridge Judge Entrepreneurship Centre, further enhancing business development skills within the pharmaceutical sector.
This person is not in any teams
This person is not in any offices
Dolon Ltd
Dolon is a leading, strategic consultancy specialising in pricing and market access for rare disease medicines. We partner and provide strategic guidance to global and national pharmaceutical companies on a variety of market access and policy issues globally. Our goal is to ensure that effective rare disease treatments are made accessible to the patients who need them, in a way that is sustainable for both the pharmaceutical industry and society. Our market access specialists deliver solutions at a therapy, disease, portfolio and industry level to realise success throughout the product life cycle. We provide services in the following areas: • Value, Price and Access • Market Access Policy • Data and Analytics Headquartered in London, and with offices globally, we are a team of enthusiastic and intellectually curious individuals who share a passion for collaboration and solving complex problems.